CSL Behring said today that it submitted a biologics license application to the U.S. Food and Drug Administration for approval to sell its part-liquid formulation of Immune Globulin Subcutaneous for weekly replacement therapy in patients with primary immunodeficiencies.
Copyright PHILY - Philly.com
